NZ703514A - Fviii peptides for immune tolerance induction and immunodiagnostics - Google Patents
Fviii peptides for immune tolerance induction and immunodiagnosticsInfo
- Publication number
- NZ703514A NZ703514A NZ703514A NZ70351411A NZ703514A NZ 703514 A NZ703514 A NZ 703514A NZ 703514 A NZ703514 A NZ 703514A NZ 70351411 A NZ70351411 A NZ 70351411A NZ 703514 A NZ703514 A NZ 703514A
- Authority
- NZ
- New Zealand
- Prior art keywords
- immune tolerance
- immunodiagnostics
- tolerance induction
- acid sequence
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40740210P | 2010-10-27 | 2010-10-27 | |
| US201161467894P | 2011-03-25 | 2011-03-25 | |
| US201161502476P | 2011-06-29 | 2011-06-29 | |
| NZ609474A NZ609474A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ703514A true NZ703514A (en) | 2017-02-24 |
Family
ID=45349271
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ703514A NZ703514A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
| NZ609474A NZ609474A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ609474A NZ609474A (en) | 2010-10-27 | 2011-10-27 | Fviii peptides for immune tolerance induction and immunodiagnostics |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8969524B2 (enExample) |
| EP (2) | EP2632479B1 (enExample) |
| JP (2) | JP6122780B2 (enExample) |
| KR (2) | KR102040867B1 (enExample) |
| CN (2) | CN104926947A (enExample) |
| AR (1) | AR083586A1 (enExample) |
| AU (2) | AU2011319747C1 (enExample) |
| BR (1) | BR112013010362A2 (enExample) |
| CA (1) | CA2815239C (enExample) |
| DK (1) | DK2632479T3 (enExample) |
| EA (1) | EA034494B1 (enExample) |
| ES (2) | ES2912455T3 (enExample) |
| HK (1) | HK1215442A1 (enExample) |
| MX (1) | MX347805B (enExample) |
| NZ (2) | NZ703514A (enExample) |
| PL (2) | PL2632479T3 (enExample) |
| PT (1) | PT2632479T (enExample) |
| SG (2) | SG10201600656WA (enExample) |
| TW (3) | TW201730205A (enExample) |
| WO (1) | WO2012058480A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| ES2626881T3 (es) * | 2012-11-12 | 2017-07-26 | Apitope International Nv | Péptidos derivados del factor VIII para uso en el tratamiento de la hemofilia A |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| EP2968499A4 (en) * | 2013-03-15 | 2016-11-30 | Haplomics Inc | COMPOSITIONS AND METHODS FOR THE IMMUNO-TOLERANCE INDUCTION FOR FACTOR VIII SPATIAL THERAPIES IN PERSONS WITH HEMOPHILIA A |
| JP6488376B2 (ja) * | 2014-06-12 | 2019-03-20 | ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬 |
| ES2869972T3 (es) * | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| CN109804432B (zh) | 2016-04-15 | 2023-07-14 | 武田药品工业株式会社 | 提供药代动力学药物给药方案的方法和设备 |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371278A1 (en) * | 2002-04-18 | 2005-06-13 | Merck Patent Gmbh | Modified factor viii |
| US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| EP2093569A3 (en) * | 2004-05-21 | 2009-11-11 | The Institute for Systems Biology | Compositions and methods for quantification of serum glycoproteins |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| WO2007077217A2 (en) | 2006-01-04 | 2007-07-12 | Baxter International Inc. | Oligopeptide-free cell culture media |
| GB0723712D0 (en) | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| US7673687B2 (en) | 2007-12-05 | 2010-03-09 | Halliburton Energy Services, Inc. | Cement compositions comprising crystalline organic materials and methods of using same |
| DE202007017320U1 (de) | 2007-12-07 | 2008-02-28 | Dittmann, Ludwig | Vorrichtung zur Raumbeduftung |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| BRPI0921429B1 (pt) | 2008-11-07 | 2022-07-12 | Takeda Pharmaceutical Company Limited | Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável |
-
2011
- 2011-10-27 KR KR1020137013231A patent/KR102040867B1/ko active Active
- 2011-10-27 EP EP11796846.1A patent/EP2632479B1/en active Active
- 2011-10-27 JP JP2013536845A patent/JP6122780B2/ja not_active Expired - Fee Related
- 2011-10-27 BR BR112013010362A patent/BR112013010362A2/pt not_active Application Discontinuation
- 2011-10-27 EP EP17167928.5A patent/EP3260132B1/en active Active
- 2011-10-27 PT PT117968461T patent/PT2632479T/pt unknown
- 2011-10-27 SG SG10201600656WA patent/SG10201600656WA/en unknown
- 2011-10-27 DK DK11796846.1T patent/DK2632479T3/en active
- 2011-10-27 AU AU2011319747A patent/AU2011319747C1/en active Active
- 2011-10-27 TW TW106113613A patent/TW201730205A/zh unknown
- 2011-10-27 EA EA201390617A patent/EA034494B1/ru not_active IP Right Cessation
- 2011-10-27 PL PL11796846T patent/PL2632479T3/pl unknown
- 2011-10-27 PL PL17167928.5T patent/PL3260132T3/pl unknown
- 2011-10-27 ES ES17167928T patent/ES2912455T3/es active Active
- 2011-10-27 NZ NZ703514A patent/NZ703514A/en unknown
- 2011-10-27 MX MX2013004753A patent/MX347805B/es active IP Right Grant
- 2011-10-27 ES ES11796846.1T patent/ES2639039T3/es active Active
- 2011-10-27 TW TW105138248A patent/TW201708251A/zh unknown
- 2011-10-27 US US13/283,452 patent/US8969524B2/en active Active
- 2011-10-27 SG SG2013028733A patent/SG189914A1/en unknown
- 2011-10-27 CA CA2815239A patent/CA2815239C/en active Active
- 2011-10-27 CN CN201510431485.4A patent/CN104926947A/zh active Pending
- 2011-10-27 KR KR1020197032106A patent/KR102222864B1/ko not_active Expired - Fee Related
- 2011-10-27 CN CN201180063117.9A patent/CN103298482B/zh active Active
- 2011-10-27 NZ NZ609474A patent/NZ609474A/en unknown
- 2011-10-27 WO PCT/US2011/058165 patent/WO2012058480A1/en not_active Ceased
- 2011-10-27 TW TW100139078A patent/TWI580430B/zh active
- 2011-10-28 AR ARP110103988A patent/AR083586A1/es not_active Application Discontinuation
-
2015
- 2015-01-23 US US14/604,622 patent/US9512198B2/en active Active
-
2016
- 2016-03-22 HK HK16103339.6A patent/HK1215442A1/zh unknown
- 2016-04-06 AU AU2016202155A patent/AU2016202155B2/en active Active
- 2016-11-02 US US15/341,936 patent/US20170267743A1/en not_active Abandoned
- 2016-11-29 JP JP2016230723A patent/JP2017095463A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| PH12012500849A1 (en) | Mycobacterial vaccines | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| IN2014KN01715A (enExample) | ||
| NZ707439A (en) | Modified factor ix polypeptides and uses thereof | |
| IN2014KN01713A (enExample) | ||
| IN2014KN01714A (enExample) | ||
| IN2014KN01716A (enExample) | ||
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| NZ609216A (en) | Anticancer fusion protein | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| NZ601488A (en) | Immunogenic proteins and compositions | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| GB201018125D0 (en) | Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: BAXALTA GMBH, CH Effective date: 20160414 Owner name: BAXALTA INC, US Effective date: 20160414 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 OCT 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20180221 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2019 BY ANAQUA SERVICES Effective date: 20180919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2020 BY ANAQUA SERVICES Effective date: 20190918 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2021 BY ANAQUA SERVICES Effective date: 20200917 |
|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP Effective date: 20210330 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2022 BY ANAQUA SERVICES Effective date: 20210921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2023 BY ANAQUA SERVICES Effective date: 20220922 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2024 BY ANAQUA SERVICES Effective date: 20230921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2025 BY ANAQUA SERVICES Effective date: 20240920 |